Bruker Given Consensus Rating of “Buy” by Analysts (NASDAQ:BRKR)
Shares of Bruker (NASDAQ:BRKR) have earned a consensus rating of “Buy” from the fourteen ratings firms that are currently covering the stock, Analyst Ratings.Net reports. Three research analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $25.60.
Shares of Bruker (NASDAQ:BRKR) opened at 20.32 on Friday. Bruker has a 52-week low of $17.75 and a 52-week high of $24.93. The stock has a 50-day moving average of $22.74 and a 200-day moving average of $22.20. The company has a market cap of $3.410 billion and a P/E ratio of 43.64.
Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Wednesday, August 6th. The company reported $0.21 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.19 by $0.02. The company had revenue of $457.40 million for the quarter, compared to the consensus estimate of $457.90 million. During the same quarter in the previous year, the company posted $0.18 earnings per share. The company’s revenue for the quarter was up .5% on a year-over-year basis. On average, analysts predict that Bruker will post $0.80 earnings per share for the current fiscal year.
BRKR has been the subject of a number of recent research reports. Analysts at Zacks downgraded shares of Bruker from an “outperform” rating to a “neutral” rating in a research note on Monday, August 11th. They now have a $25.40 price target on the stock. Separately, analysts at Citigroup Inc. initiated coverage on shares of Bruker in a research note on Thursday, July 17th. They set a “buy” rating on the stock. Finally, analysts at ISI Group downgraded shares of Bruker from a “buy” rating to a “neutral” rating in a research note on Tuesday, July 8th. They now have a $25.50 price target on the stock.
Bruker Corporation (NASDAQ:BRKR) is a global manufacturer of scientific instruments that address the rapidly evolving needs of a diverse array of customers in life science, pharmaceutical, biotechnology, clinical and molecular diagnostics research, as well as in materials and chemical analysis in various industries and government applications.
Receive News & Ratings for Bruker Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Co and related companies with Analyst Ratings Network's FREE daily email newsletter.